tirzepatide

The effectiveness of Tirzepatide (Mounjaro) as a treatment for diabetes and obesity among diabetic patients was evaluated in a series of Phase 3 clinical trials known as the SURPASS studies. These trials examined the medication’s efficacy both as a standalone treatment, as an adjunct to other medications, or compared directly with alternative therapies.

Here is a summary of the studies:

SURPASS 1 Study – examined the effectiveness of Tirzepatide as a standalone treatment at three different doses (5 mg, 10 mg, and 15 mg) among patients with type 2 diabetes who had elevated hemoglobin A1C despite following balanced nutrition and regular physical activity. After 40 weeks, results indicated a significant improvement in blood sugar regulation and body weight without increasing the risk of hypoglycemia (a sharp drop in blood sugar levels). Tirzepatide showed a dose-dependent weight loss ranging from 7 to 9.5 kg. Additionally, up to 92% of participants taking Tirzepatide achieved an A1C level below 7%, and up to 52% reached levels below 5.7%. Thus, Tirzepatide demonstrated considerable effectiveness in controlling blood sugar and reducing body weight.

SURPASS 2 Study – evaluated Tirzepatide’s efficacy at the same three dosages compared to a weekly injection of 1 mg semaglutide, the active ingredient in Ozempic (Wegovy also contains semaglutide, but at a higher dosage of 2.4 mg for weight loss). After 40 weeks, Tirzepatide was associated with significantly greater reductions in body weight and hemoglobin A1C levels compared to semaglutide (Ozempic 1 mg). Additionally, all three Tirzepatide doses positively influenced blood lipid levels, including triglycerides, bad cholesterol (VLDL), and good cholesterol (HDL).

• Participants taking Tirzepatide at a 5 mg dose lost an average of 7.8 kg.
• Participants taking Tirzepatide at a 10 mg dose lost an average of 10.3 kg.
• Participants taking Tirzepatide at a 15 mg dose lost an average of 12.5 kg.

In contrast, participants receiving Semaglutide (Ozempic 1 mg) lost only 6.2 kg on average.

Further analysis of the study showed that 60% of participants on Tirzepatide 15 mg and 51% on Tirzepatide 10 mg lost at least 10% of their initial body weight.

SURPASS 3 Study – This study evaluated the efficacy of Tirzepatide compared to insulin degludec among diabetic patients with poorly controlled blood sugar levels on metformin (Glucophage). Results indicated that Tirzepatide at the highest dosage (15 mg) led to a significantly greater reduction in hemoglobin A1C compared to insulin degludec. Participants taking Tirzepatide lost an average of 7.5 kg (5 mg dose), 10.5 kg (10 mg dose), and 12.9 kg (15 mg dose), whereas the insulin degludec group experienced an average weight gain of 2.3 kg.

SURPASS 4 Study – In this trial, involving participants at increased cardiovascular risk, all three Tirzepatide dosages achieved greater reductions in hemoglobin A1C compared to insulin glargine. Additionally, treatment with Tirzepatide resulted in significantly greater weight loss.

SURPASS 5 Study – Participants in this trial were type 2 diabetes patients treated with insulin glargine, with or without metformin. After 40 weeks, adding Tirzepatide at a 15 mg dose to insulin glargine significantly lowered hemoglobin A1C by 2.59% compared to only 0.93% in the placebo group. Tirzepatide also led to an average weight loss of 10.9 kg and allowed for a reduction in insulin dosage, compared to the placebo group, which saw an average weight gain of 1.7 kg and a 75% increase in insulin dosage.